Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Mark A. Stang who wrote (11008)	7/9/1998 6:38:00 PM
From: VLAD	Read Replies (1) \| Respond to of 23519

<<this stock will see 5 1/2 tomorrow>> Mark, You may be right and you may be wrong. I expect an initial sell off followed by some serious accumulating. Many miss an important point--J&J and Astra can not afford to see Vivus crawl in the mud. They both need a healthy Vivus to supply their international markets and they know that there is serious potential for good money to be made if they partner domestically. It costs more than current market cap to get one drug from R&D to FDA approval. I do not know what the worth of Alibra or the potential genetic product is. We are all tiny fish in a big ocean. I think that many institutions will now accumulate Vivus on any weakness as a buy out speculation or for the fact that things are now at their worse and can and will improve throughout the year.